Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

SHP465

- PMLiVE

Thomas Dittrich takes up CFO role at Shire

He also joins the Irish biotech’s board

- PMLiVE

Shire wins CHMP backing for Adynovi

Haemophilia A treatment backed for European approval

- PMLiVE

Shire’s gene therapy candidate receives orphan drug status in the US

Investigational factor VIII treatment SHP654 is being developed for haemophilia

Shire promotes Joanne Cordeiro to chief human resources officer

But loses CFO Jeff Poulton, who is moving to Boston start-up Indigo

- PMLiVE

Shire to customise MicroHealth’s app for haemphilia patients

Will collaborate with the digital health firm on its mobile monitoring tool

Shire Basingstoke

Shire files dry eye drug lifitegrast in Europe

Analysts predict Xiidra could become a $1bn product

- PMLiVE

Shire strikes bi-specific antibody deal with Novimmune

Pharma giant obtains licence for haemophilia A candidate

- PMLiVE

Shire wins block of Roche’ ‘misinformation’ over emicizumab

Obtains a preliminary injunction from a German court

- PMLiVE

Shire claims FDA approval for slow-cooked ADHD drug

Mydayis will reach the US market in the third quarter of the year

- PMLiVE

Shire licences Parion dry eye drug in $535m deal

Bolsters the Irish group's ophthalmic portfolio

Shire Basingstoke

Shire finally bags EU approval for rare disease drug Natpar

Becomes first licenced treatment for hypoparathyroidism in Europe

National Institute for Health and Care Excellence NICE logo

NICE knocks-back Shire’s pancreatic cancer drug Onivyde

Final guidance rules it's not a cost-effective use of NHS resources

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links